Late breast cancer recurrence risk

EndoPredict® Breast Cancer Prognostic Test is the only test able to predict risk of recurrence up to 15 years, allowing clinicians and their patients to predict the future and make safe treatment choices today.1

Information for clinicians

Can breast cancer relapse after 15 years?

EndoPredict provides the most accurate prediction of long-term recurrence risk in breast cancer2

EndoPredict is the only second generation breast cancer prognostic test validated for premenopausal AND postmenopausal women with early-stage breast cancer that is ER positive, HER2 negative, node negative or positive1,3-8 – and the first second generation test with level of evidence 1A data.9,10

EndoPredict is the only test to provide recurrence risk data for 5-15 years1, giving additional peace-of-mind for patient safety and helping clinicians decide if long-term adjuvant endocrine therapy can be avoided.

If you are a patient, please ask your doctor if the EndoPredict test is right for you, or visit our patient homepage for more information.

Is long-term adjuvant hormone therapy necessary for every breast cancer patient?

What is the risk of breast cancer relapsing after treatment?

Breast cancer recurrence risk continues beyond 5 years of endocrine therapy. More than 50% of late recurrences in women with ER positive/HER2 negative disease occur after 5 years’ endocrine treatment.11

Accurate long-term prognosis is therefore crucial to help clinicians to decide if stopping hormone therapy with their breast cancer patient is the right decision.

Choose EndoPredict, the only prognostic test to accurately predict early and late breast cancer recurrence

EndoPredict is the only prognostic test that accurately predicts late recurrence risk in breast cancer patients, regardless of positive lymph nodes and even for women distant recurrence-free at 5 years1 – for decisions going beyond adjuvant chemotherapy.

This study assessed the ability of EPclin to predict early and late recurrence in 1,072 postmenopausal women with early-stage ER positive/HER2 negative breast cancer enrolled in the randomized phase III ABCSG-6 and ABCSG-8 trials using a follow-up of up to 15 years:

  • All patients received five years of adjuvant endocrine therapy only (tamoxifen or tamoxifen + anastrozole)
  • Estimated 5-15 years distant recurrence free risk (DRFR) in patients recurrence-free after 5 years was 95.7% EPclin Risk Score low-risk versus 84.1% EPclin Risk Score high-risk

EndoPredict is a second generation test that incorporates more than other tests

EPclin Risk Score

The EPclin Risk Score combines clinical and molecular factors for enhanced prognostic performance, supporting accurate decisions.4

The 12-Gene Molecular Score monitors for genes selected to optimize prediction of early and late recurrence (0-15 years) – this is why EndoPredict provides the most accurate long-term recurrence risk for breast cancer.1,8

How does the EndoPredict breast cancer test work?

The EndoPredict animated app can show you how various gene activities in the tumor influence the prognosis and how the molecular fingerprint and tumor size and nodal status contribute to the final EndoPredict result.

EndoPredict second generation test can be performed locally within a few days

EndoPredict Breast Cancer Prognostic Test is available to order by clinicians via numerous local labs in your country or outside of the EU also via Myriad Genetics’ central laboratory in Salt Lake City, USA.


  1. Filipits, Martin et al. “Prediction Of Distant Recurrence Using Endopredict Among Women With ER+, HER2− Node-Positive And Node-Negative Breast Cancer Treated With Endocrine Therapy Only“. Clinical Cancer Research, vol 25, no. 13, 2019, pp. 3865-3872
  2. Sestak, Ivana et al. “Comparison Of The Performance Of 6 Prognostic Signatures For Estrogen Receptor–Positive Breast Cancer“. JAMA Oncology, vol 4, no. 4, 2018, pp. 545-553
  3. Constantinidou, Anastasia et al. “Clinical Validation Of Endopredict In Premenopausal Women With Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer.“. Journal Of Clinical Oncology, vol 39, no. 15_suppl, 2021, pp. 537-537
  4. Filipits, Martin et al. “A New Molecular Predictor Of Distant Recurrence In ER-Positive, HER2-Negative Breast Cancer Adds Independent Information To Conventional Clinical Risk Factors“. Clinical Cancer Research, vol 17, no. 18, 2011, pp. 6012-6020
  5. Buus, Richard et al. “Comparison Of Endopredict And Epclin With Oncotype DX Recurrence Score For Prediction Of Risk Of Distant Recurrence After Endocrine Therapy“. Journal Of The National Cancer Institute, vol 108, no. 11, 2016, p. djw149
  6. Sestak, Ivana et al. “Prediction Of Chemotherapy Benefit By Endopredict In Patients With Breast Cancer Who Received Adjuvant Endocrine Therapy Plus Chemotherapy Or Endocrine Therapy Alone“. Breast Cancer Research And Treatment, vol 176, no. 2, 2019, pp. 377-386
  7. Martin, Miguel et al. “Clinical Validation Of The Endopredict Test In Node-Positive, Chemotherapy-Treated ER+/HER2− Breast Cancer Patients: Results From The GEICAM 9906 Trial“. Breast Cancer Research, vol 16, no. 2, 2014, p. R38
  8. Dubsky, Peter et al. “The Endopredict Score Provides Prognostic Information On Late Distant Metastases In ER+/HER2− Breast Cancer Patients“. British Journal Of Cancer, vol 109, no. 12, 2013, pp. 2959-2964
  9. Penault-Llorca, Frederique et al. “Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of *** (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC)“. SABCS 2021, PD-09-08 Spotlight Poster Discussion 9
  10. Simon, Richard et al. “Use Of Archived Specimens In Evaluation Of Prognostic And Predictive Biomarkers”. Journal Of The National Cancer Institute, vol 101, no. 21, 2009, pp. 1446-1452
  11. Pan, Hongchao et al. “20-Year Risks Of Breast-Cancer Recurrence After Stopping Endocrine Therapy At 5 Years“. New England Journal Of Medicine, vol 377, no. 19, 2017, pp. 1836-1846